AUTHORS
Changju Qu, PhD, Ping Nana2, Qian Zhu3, Junhong Li4, Xiao Zhang5, Fan Xia6, Rui Zou7, Siyun He8, Depei Wu Sr, MD9, Zhengming Jin10
AFFILIATIONS
1 National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University,Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China
2 National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University,Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China
3 National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University,Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China
4 National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University,Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China
5 National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University,Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China
6 The First Affiliated Hospital of Soochow University, Suzhou, China
7 National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University,Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China
8 National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University,Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China
9 National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University,Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China
10 National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University,Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China
ABSTRACT
Introduction: Treatment options for elderly unfit/frail patients with diffuse large B-cell lymphoma (DLBCL) are limited due to comorbidities or functional decline. Less toxic and effective alternatives to standard rituximab plus attenuated cyclophosphamide, doxorubicin, vincristine, and prednisone (R-miniCHOP) are needed (Frédéric Peyrade Lancet Oncol 2011). The combination of pomalidomide, rituximab, and orelabrutinib (PRO) with miniCHOP represented a promising treatment option for elderly DLBCL patients, with favorable efficacy and acceptable safety profiles, particularly among those who responded to induction therapy of PRO in our prevous report (Changju Qu 2025 ASH) . Polatuzumab vedotin (Pola), a CD79b-targeted antibody-drug conjugate, enabled targeted delivery of the cytotoxic payload monomethyl auristatin E (MMAE), potentially enhancing antitumor activity while limiting systemic toxicity (Deeks ED Drugs 2019). Herein, we aimed to evaluate the efficacy and safety of the PRO plus Pola (PRO-Pola) in elderly unfit/frail patients with newly diagnosed DLBCL.
Methods: This open-label, single-arm, phase II trial (NCT07072208) enrolled previously untreated, unfit/frail patients aged ≥70 years with DLBCL. Eligible patients received induction therapy of one 21-day cycle of PRO (pomalidomide 4 mg on days 1–7; rituximab 375 mg/m² on day 1; orelabrutinib 150 mg once daily). Thereafter, patients who achieved at least a minimal response (miniR, defined as a 25%–50% reduction in tumor lesions) received six cycles of consolidation therapy of PRO-Pola (Pola, 1.8 mg/kg on day 1). The primary endpoint was complete response (CR) rate (CRR) after 6 cycles of PRO-Pola; secondary endpoints included overall response rate (ORR) after 6 cycles of PRO-Pola, 2-year progression-free survival (PFS), 2-year overall survival (OS), and safety.
Results: As of July 23, 2026, 19 patients (males/females, 11/8) were enrolled, with a median age of 77.0 years (range, 70.0–91.0). The majority of paients were International Prognostic Index score of 3-5 (63.2%, n=12), stage III-IV (78.9%, n=15), extranodal involvement (84.2%, n=16), and a non-germinal center B-cell-like subtype (52.6%, n=10). MYC/BCL2 double expression was observed in 9 patients (47.4%). Among the 11 patients with available genetic profiling, MCD subtype was the most common (63.6%, n=7), followed by BN2/MCD, BN2, ST2, and TP53 inactivation (each 9.1%, n=1). All patients achieved miniR after PRO induction therapy (n=19), and the CRR and ORR were 31.6% (95% confidence interval [CI], 12.6-56.6) and 89.5% (95% CI, 66.9-98.7), respectively, with 6 CR, 11 partial response (PR), and 2 miniR. Eighteen patients completed 3 cycles of PRO-Pola therapy, achieving a CRR of 77.8% (95% CI, 52.4-93.6) and an ORR of 94.4% (95% CI, 72.7-99.9). A total of 78.9% of patients (n=15) completed 6 cycles of PRO-Pola as planned; two withdrew consent, and one switched to another regimen after achieving stable disease. Responses were observed in all patients, with the CRR and ORR both 100.0% (95% CI, 78.2–100.0). After a median follow-up of 14.5 months (95% CI, 11.1-17.9), the 1-year PFS and OS were 89.2% (95% CI, 63.1-97.2) and 94.4% (95% CI, 66.6-99.2), respectively, with median PFS and OS not reached. Adverse events (AEs) of any grade were observed in 18 (94.7%) patients, with 10 patients (52.6%) reporting grade ≥3 AEs. The most common AEs were anemia (any grade, 84.2%; grade ≥3, 10.5%) and neutrophil count decreased (any grade, 68.4%; grade ≥3, 47.4%).
Conclusions: PRO-Pola achieved high CRR and ORR with an expected and manageable safety profile, translating into favorable 1-year survival rates in elderly frail/unfit patients with DLBCL. These findings supported its further clinical evaluation as a frontline option for this vulnerable patient population.
DISCLOSURES
Changju Qu, PhD: No relevant conflicts of interest to declare.